Study of tacabrutideg in people with liver problems
This study tests an experimental drug called tacabrutideg in people with moderate or severe liver damage, as well as in people with normal liver function. The goal is to see how the drug is processed by the body and whether it is safe to take when your liver is not working normally.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old (and your weight is within a healthy range for your height).
- You have stable liver disease (moderate or severe) or have normal liver function.
- You have not taken any other BTK protein degrader drugs before.
- You do not have any serious bleeding disorders or unexplained bleeding problems.
- You must not be pregnant or planning to become pregnant, and men must use condoms during the study.
- You do not have a history of liver transplant, liver cancer, or certain bile duct diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
This study looks at how a new drug, casdatifan, is processed in the body in people with moderate liver problems compared to healthy people. Understanding this helps doctors decide if the drug is safe and how to dose it for patients with liver issues.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This study tests how a new drug (AZD4144) is processed by the body in people with different levels of liver function. It aims to see if the drug is safe and how the liver affects its levels, which may help guide future dosing for patients with liver problems.
This study tests how the body handles the medicine Atirmociclib in people with different levels of liver function, from normal to moderate or severe liver disease. It helps doctors understand if the dose needs to be adjusted for people with liver problems.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.